Longitudinal viral shedding and antibody response characteristics of men with acute infection of monkeypox virus: a prospective cohort study.

Humans Male Virus Shedding Antibodies, Viral / immunology Prospective Studies Adult Monkeypox virus / immunology Mpox (monkeypox) / immunology Saliva / virology HIV Infections / immunology Antibodies, Neutralizing / immunology Middle Aged Longitudinal Studies DNA, Viral Oropharynx / virology Coinfection / immunology Viral Load Fomites / virology

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
27 May 2024
Historique:
received: 16 01 2024
accepted: 13 05 2024
medline: 28 5 2024
pubmed: 28 5 2024
entrez: 27 5 2024
Statut: epublish

Résumé

Understanding of infection dynamics is important for public health measures against monkeypox virus (MPXV) infection. Herein, samples from multiple body sites and environmental fomites of 77 acute MPXV infections (HIV co-infection: N = 42) were collected every two to three days and used for detection of MPXV DNA, surface protein specific antibodies and neutralizing titers. Skin lesions show 100% positivity rate of MPXV DNA, followed by rectum (88.16%), saliva (83.78%) and oropharynx (78.95%). Positivity rate of oropharynx decreases rapidly after 7 days post symptom onset (d.p.o), while the rectum and saliva maintain a positivity rate similar to skin lesions. Viral dynamics are similar among skin lesions, saliva and oropharynx, with a peak at about 6 d.p.o. In contrast, viral levels in the rectum peak at the beginning of symptom onset and decrease rapidly thereafter. 52.66% of environmental fomite swabs are positive for MPXV DNA, with highest positivity rate (69.89%) from air-conditioning air outlets. High seropositivity against A29L (100%) and H3L (94.74%) are detected, while a correlation between IgG endpoint titers and neutralizing titers is only found for A29L. Most indexes are similar between HIV and Non-HIV participants, while HIV and rectitis are associated with higher viral loads in rectum.

Identifiants

DOI: 10.1038/s41467-024-48754-8 PMID: 38802350
pubmed: 38802350
doi: 10.1038/s41467-024-48754-8
pii: 10.1038/s41467-024-48754-8
doi:

Substances chimiques

Antibodies, Viral 0
Antibodies, Neutralizing 0
DNA, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4488

Subventions

Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 32170936

Informations de copyright

© 2024. The Author(s).

Références

Mitjà, O. et al. Monkeypox. Lancet 401, 60–74 (2023).
pubmed: 36403582 doi: 10.1016/S0140-6736(22)02075-X
Reed, K. D. et al. The detection of monkeypox in humans in the Western Hemisphere. N. Engl. J. Med. 350, 342–350 (2004).
pubmed: 14736926 doi: 10.1056/NEJMoa032299
Isidro, J. et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat. Med. 28, 1569–1572 (2022).
pubmed: 35750157 pmcid: 9388373 doi: 10.1038/s41591-022-01907-y
Lum, F. M. et al. Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat. Rev. Immunol. 22, 597–613 (2022).
pubmed: 36064780 pmcid: 9443635 doi: 10.1038/s41577-022-00775-4
Zhao, H. et al. The First Imported Case of Monkeypox in the Mainland of China - Chongqing Municipality, China, September 16, 2022. China CDC Wkly 4, 853–854 (2022).
pubmed: 36284686 pmcid: 9579970
Dou, X. et al. Clinical, epidemiological, and virological features of Mpox in Beijing, China - May 31-June 21, 2023. Emerg. Microbes Infect. 12, 2254407 (2023).
pubmed: 37649257 pmcid: 10494722 doi: 10.1080/22221751.2023.2254407
Wan, J. et al. Investigation into the epidemiology, genetic characteristics, and clinical manifestations of the first monkeypox outbreak in Shenzhen, China. Biosaf. Health 5, 259–265 (2023).
doi: 10.1016/j.bsheal.2023.08.001
Xu, T. & Zhang, L. Rising prevalence of mpox in China, Japan, and Republic of Korea. J. Infect. 87, e73–e74 (2023).
pubmed: 37532030 doi: 10.1016/j.jinf.2023.07.017
Beeson, A. et al. Mpox respiratory transmission: the state of the evidence. Lancet Microbe 4, e277–e283 (2023).
pubmed: 36898398 pmcid: 9991082 doi: 10.1016/S2666-5247(23)00034-4
Suñer, C. et al. Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain. Lancet Infect. Dis. 23, 445–453 (2023).
pubmed: 36521505 doi: 10.1016/S1473-3099(22)00794-0
Towns, J. M. et al. Persistence of monkeypox virus at oral and rectal sites. Lancet Microbe 4, e210 (2023).
pubmed: 36642085 pmcid: 9836426 doi: 10.1016/S2666-5247(22)00382-2
Palich, R. et al. Viral loads in clinical samples of men with monkeypox virus infection: a French case series. Lancet Infect. Dis. 23, 74–80 (2023).
pubmed: 36183707 doi: 10.1016/S1473-3099(22)00586-2
Hernaez, B. et al. Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study. Lancet Microbe 4, e21–e28 (2023).
pubmed: 36436538 doi: 10.1016/S2666-5247(22)00291-9
Callaby, H. et al. Monkeypox virus isolation from longitudinal samples from four patients to infer risk of onwards transmission: an interim analysis. J. Hosp. Infect. 135, 139–144 (2023).
pubmed: 36958701 pmcid: 10029343 doi: 10.1016/j.jhin.2023.03.009
Peiró-Mestres, A. et al. Frequent detection of monkeypox virus DNA in saliva, semen, and other clinical samples from 12 patients, Barcelona, Spain, May to June 2022. Eur. Surveill. 27, 2200503 (2022).
doi: 10.2807/1560-7917.ES.2022.27.28.2200503
Lapa, D. et al. Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding. Lancet Infect. Dis. 22, 1267–1269 (2022).
pubmed: 35931095 pmcid: 9629691 doi: 10.1016/S1473-3099(22)00513-8
Hasso, M. et al. Monkeypox Virus Detection in Different Clinical Specimen Types. Emerg. Infect. Dis. 28, 2513–2515 (2022).
pubmed: 36223653 pmcid: 9707591 doi: 10.3201/eid2812.221160
Rizzo, A. et al. Role of multi-site sampling in the diagnosis of human Monkeypox. J. Infect. 86, 154–225 (2023).
pubmed: 36521564 doi: 10.1016/j.jinf.2022.12.010
Ferré VM et al. Detection of Monkeypox Virus in Anorectal Swabs From Asymptomatic Men Who Have Sex With Men in a Sexually Transmitted Infection Screening Program in Paris, France. Ann. Intern Med. 175, 1491–1492 (2022).
pubmed: 35969863 doi: 10.7326/M22-2183
De Baetselier, I. et al. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat. Med. 28, 2288–2292 (2022).
pubmed: 35961373 pmcid: 9671802 doi: 10.1038/s41591-022-02004-w
Reda, A., El-Qushayri, A. E. & Shah, J. Asymptomatic monkeypox infection: a call for greater control of infection and transmission. Lancet Microbe 4, e15–e16 (2023).
pubmed: 36209756 doi: 10.1016/S2666-5247(22)00259-2
Otu, A., Ebenso, B., Walley, J., Barceló, J. M. & Ochu, C. L. Global human monkeypox outbreak: atypical presentation demanding urgent public health action. Lancet Microbe 3, e554–e555 (2022).
pubmed: 35688169 pmcid: 9550615 doi: 10.1016/S2666-5247(22)00153-7
Nakhaie, M. et al. Monkeypox virus diagnosis and laboratory testing. Rev. Med Virol. 33, e2404 (2023).
pubmed: 36331049 doi: 10.1002/rmv.2404
Adler, H. et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect. Dis. 22, 1153–1162 (2022).
pubmed: 35623380 pmcid: 9300470 doi: 10.1016/S1473-3099(22)00228-6
Huang, Y., Mu, L. & Wang, W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. Signal Transduct. Target Ther. 7, 373 (2022).
pubmed: 36319633 pmcid: 9626568 doi: 10.1038/s41392-022-01215-4
Rao, A. K. et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb. Mortal. Wkly Rep. 71, 734–742 (2022).
pubmed: 35653347 pmcid: 9169520 doi: 10.15585/mmwr.mm7122e1
Xu, M. et al. Real-world effectiveness of monkeypox vaccines: a systematic review. J. Travel Med. 30, taad048 (2023).
pubmed: 37040341 doi: 10.1093/jtm/taad048
Zaeck, L. M. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat. Med. 29, 270–278 (2023).
pubmed: 36257333 doi: 10.1038/s41591-022-02090-w
Wang, Y., Yang, K. & Zhou, H. Immunogenic proteins and potential delivery platforms for mpox virus vaccine development: A rapid review. Int J. Biol. Macromol. 245, 125515 (2023).
pubmed: 37353117 doi: 10.1016/j.ijbiomac.2023.125515
Yu, J. et al. Phylogeny and molecular evolution of the first local monkeypox virus cluster in Guangdong Province, China. Nat. Commun. 14, 8241 (2023).
pubmed: 38086870 pmcid: 10716143 doi: 10.1038/s41467-023-44092-3
Sahay, R. R. et al. Persistence of infectious mpox virus on the surfaces of isolation ward in a hospital setting, India. J. Hosp. Infect. 137, 86–88 (2023).
pubmed: 37120071 pmcid: 10133095 doi: 10.1016/j.jhin.2023.03.026
Pfeiffer, J. A. et al. High-Contact Object and Surface Contamination in a Household of Persons with Monkeypox Virus Infection - Utah, June 2022. MMWR Morb. Mortal. Wkly Rep. 71, 1092–1094 (2022).
pubmed: 36006842 pmcid: 9422960 doi: 10.15585/mmwr.mm7134e1
Zhao, F. et al. The Time Sequences of Respiratory and Rectal Viral Shedding in Patients With Coronavirus Disease 2019. Gastroenterology 159, 1158–1160.e1152 (2020).
pubmed: 32425226 doi: 10.1053/j.gastro.2020.05.035
Yang, Y. et al. Laboratory Diagnosis and Monitoring the Viral Shedding of SARS-CoV-2 Infection. Innov. (Camb.) 1, 100061 (2020).
Lim, C. K. et al. Mpox diagnostics: Review of current and emerging technologies. J. Med Virol. 95, e28429 (2023).
pubmed: 36571266 pmcid: 10108241 doi: 10.1002/jmv.28429
Colavita, F. et al. Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak. J. Med Virol. 95, e28851 (2023).
pubmed: 37287343 doi: 10.1002/jmv.28851
Cohn, H. et al. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study. Lancet Infect. Dis. 23, 1302–1312 (2023).
pubmed: 37475115 doi: 10.1016/S1473-3099(23)00352-3
Yang, Y. et al. Viral and antibody dynamics of acute infection with SARS-CoV-2 omicron variant (B.1.1.529): a prospective cohort study from Shenzhen, China. Lancet Microbe 4, e632–e641 (2023).
pubmed: 37459867 doi: 10.1016/S2666-5247(23)00139-8
Antinori, A. et al. Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022. Eur. Surveill. 27, 2200421 (2022).
doi: 10.2807/1560-7917.ES.2022.27.22.2200421
Thornhill, J. P. et al. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N. Engl. J. Med. 387, 679–691 (2022).
pubmed: 35866746 doi: 10.1056/NEJMoa2207323
Patel, A. et al. Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series. Bmj 378, e072410 (2022).
pubmed: 35902115 pmcid: 9331915 doi: 10.1136/bmj-2022-072410
Tarín-Vicente, E. J. et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet 400, 661–669 (2022).
pubmed: 35952705 pmcid: 9533900 doi: 10.1016/S0140-6736(22)01436-2
Català, A. et al. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases. Br. J. Dermatol 187, 765–772 (2022).
pubmed: 35917191 doi: 10.1111/bjd.21790
Lim, C. K. et al. Correlation between monkeypox viral load and infectious virus in clinical specimens. J. Clin. Virol. 161, 105421 (2023).
pubmed: 36893717 pmcid: 9981273 doi: 10.1016/j.jcv.2023.105421
Paran, N. et al. Monkeypox DNA levels correlate with virus infectivity in clinical samples, Israel, 2022. Eur. Surveill. 27, 2200636 (2022).
doi: 10.2807/1560-7917.ES.2022.27.35.2200636
Moschese, D. et al. Isolation of viable monkeypox virus from anal and urethral swabs, Italy, May to July 2022. Eur. Surveill. 27, 2200675 (2022).
doi: 10.2807/1560-7917.ES.2022.27.36.2200675
Kim, H. et al. Viral load dynamics and shedding kinetics of mpox infection: a systematic review and meta-analysis. J. Travel Med. 30, taad111 (2023).
pubmed: 37581603 doi: 10.1093/jtm/taad111
Kelley, C. F. et al. The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: implications for HIV transmission and prevention. Mucosal. Immunol. 10, 996–1007 (2017).
pubmed: 27848950 doi: 10.1038/mi.2016.97
Gould, S. et al. Air and surface sampling for monkeypox virus in a UK hospital: an observational study. Lancet Microbe 3, e904–e911 (2022).
pubmed: 36215984 pmcid: 9546519 doi: 10.1016/S2666-5247(22)00257-9
Atkinson, B. et al. Infection-competent monkeypox virus contamination identified in domestic settings following an imported case of monkeypox into the UK. Environ. Microbiol 24, 4561–4569 (2022).
pubmed: 35837859 pmcid: 9796424 doi: 10.1111/1462-2920.16129
Ogoina, D. & Ogunsola, F. T. Monkeypox and the health-care environment. Lancet Microbe 3, e889–e890 (2022).
pubmed: 36215985 pmcid: 9546517 doi: 10.1016/S2666-5247(22)00286-5
Freyn, A. W. et al. An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med. 15, eadg3540 (2023).
pubmed: 37792954 doi: 10.1126/scitranslmed.adg3540
Zeng, J. et al. Mpox multi-antigen mRNA vaccine candidates by a simplified manufacturing strategy afford efficient protection against lethal orthopoxvirus challenge. Emerg. Microbes Infect. 12, 2204151 (2023).
pubmed: 37070521 pmcid: 10167873 doi: 10.1080/22221751.2023.2204151
Zhang, R. R. et al. Rational development of multicomponent mRNA vaccine candidates against mpox. Emerg. Microbes Infect. 12, 2192815 (2023).
pubmed: 36947428 pmcid: 10071941 doi: 10.1080/22221751.2023.2192815
Fang, Z. et al. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res. 33, 407–410 (2023).
pubmed: 36879038 pmcid: 9988199 doi: 10.1038/s41422-023-00792-5
Yang, X. et al. Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice. J. Med Virol. 95, e29140 (2023).
pubmed: 37800627 doi: 10.1002/jmv.29140
Hou, F. et al. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge. Nat. Commun. 14, 5925 (2023).
pubmed: 37739969 pmcid: 10516993 doi: 10.1038/s41467-023-41628-5
Yang, X. et al. A Subunit Vaccine Candidate Composed of Mpox Virus A29L, M1R, A35R, and B6R Elicits Robust Immune Response in Mice. Vaccines (Basel) 11, 1420 (2023).
pubmed: 37766097 doi: 10.3390/vaccines11091420
Jiang, Y. et al. Various mpox recombinant subunits induce broadly reactive antibodies against orthopoxvirus in mice. J. Med. Virol. 95, e28983 (2023).
pubmed: 37503573 doi: 10.1002/jmv.28983
Yang, Y. et al. Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2. Signal Transduct. Target Ther. 7, 316 (2022).
pubmed: 36085321 pmcid: 9462069 doi: 10.1038/s41392-022-01166-w
Hubert, M. et al. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. Cell Host Microbe 31, 937–948.e934 (2023).
pubmed: 37196656 pmcid: 10188274 doi: 10.1016/j.chom.2023.05.001
Igor Moraes-Cardoso, et al. Immune Responses Associated with Mpox Viral Clearance in a Prospective Observational Cohort of People With and Without HIV in Spain. Lancet. Microbe. 5 (2024) In press.
Pan, D. et al. Monkeypox in the UK: arguments for a broader case definition. Lancet 399, 2345–2346 (2022).
pubmed: 35716671 pmcid: 9528227 doi: 10.1016/S0140-6736(22)01101-1
Beer, E. M. & Rao, V. B. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. PLoS Negl. Trop. Dis. 13, e0007791 (2019).
pubmed: 31618206 pmcid: 6816577 doi: 10.1371/journal.pntd.0007791
Petersen, E. et al. Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect. Dis. Clin. North Am. 33, 1027–1043 (2019).
pubmed: 30981594 pmcid: 9533922 doi: 10.1016/j.idc.2019.03.001
Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl. Trop. Dis. 16, e0010141 (2022).
pubmed: 35148313 pmcid: 8870502 doi: 10.1371/journal.pntd.0010141
Jezek, Z., Grab, B. & Dixon, H. Stochastic model for interhuman spread of monkeypox. Am. J. Epidemiol. 126, 1082–1092 (1987).
pubmed: 2825518 doi: 10.1093/oxfordjournals.aje.a114747
Elsayed, S., Bondy, L. & Hanage, W. P. Monkeypox Virus Infections in Humans. Clin. Microbiol Rev. 35, e0009222 (2022).
pubmed: 36374082 doi: 10.1128/cmr.00092-22
Endo, A. et al. Heavy-tailed sexual contact networks and monkeypox epidemiology in the global outbreak, 2022. Science 378, 90–94 (2022).
pubmed: 36137054 doi: 10.1126/science.add4507
Xu, Z. et al. Development of a quadruple qRT-PCR assay for simultaneous identification of hypervirulent and carbapenem-resistant Klebsiella pneumoniae. Microbiol Spectr. 12, e0071923 (2024).
pubmed: 38059628 doi: 10.1128/spectrum.00719-23
Li, T. et al. Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nat. Commun. 12, 5652 (2021).
pubmed: 34580306 pmcid: 8476643 doi: 10.1038/s41467-021-25997-3
Yang, Y. et al. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat. Microbiol. 7, 423–433 (2022).
pubmed: 35132197 doi: 10.1038/s41564-021-01051-2

Auteurs

Yang Yang (Y)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China. young@mail.sustech.edu.cn.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China. young@mail.sustech.edu.cn.
National Clinical Research Center for Infectious Disease, Shenzhen, China. young@mail.sustech.edu.cn.
ORCID: 0000-0002-6489-4459

Shiyu Niu (S)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.
National Clinical Research Center for Infectious Disease, Shenzhen, China.

Chenguang Shen (C)

BSL-3 Laboratory (Guangdong), Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health; Department of Laboratory Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
ORCID: 0000-0001-8607-3750

Liuqing Yang (L)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.

Shuo Song (S)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.
ORCID: 0000-0002-0289-2941

Yun Peng (Y)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.

Yifan Xu (Y)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.

Liping Guo (L)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.

Liang Shen (L)

Department of Central Laboratory, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, Hubei, China.

Zhonghui Liao (Z)

School of Public Health, Bengbu Medical College, Bengbu, Anhui, China.

Jiexiang Liu (J)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.

Shengjie Zhang (S)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.
ORCID: 0000-0001-6988-2791

Yanxin Cui (Y)

School of Public Health, Bengbu Medical College, Bengbu, Anhui, China.

Jiayin Chen (J)

National Clinical Research Center for Infectious Disease, Shenzhen, China.

Si Chen (S)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.

Ting Huang (T)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China.

Fuxiang Wang (F)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China. 13927486077@163.com.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China. 13927486077@163.com.
National Clinical Research Center for Infectious Disease, Shenzhen, China. 13927486077@163.com.
ORCID: 0000-0002-2605-3747

Hongzhou Lu (H)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China. luhongzhou@szsy.sustech.edu.cn.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China. luhongzhou@szsy.sustech.edu.cn.
National Clinical Research Center for Infectious Disease, Shenzhen, China. luhongzhou@szsy.sustech.edu.cn.

Yingxia Liu (Y)

Shenzhen Key Laboratory of Pathogen and Immunity, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China. yingxialiu@hotmail.com.
Guangdong Key Laboratory for Diagnosis and Treatment of Emerging Infectious diseases, Shenzhen, China. yingxialiu@hotmail.com.
ORCID: 0000-0001-6335-3346

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Phénomènes physiologiques › Excrétion virale › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Virus › Virus à ADN › Poxviridae › Chordopoxvirinae › Orthopoxvirus › Virus de la variole simienne › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Liquides et sécrétions biologiques › Sécrétions corporelles › Salive › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › ADN viral › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Système stomatognathique › Pharynx › Partie orale du pharynx › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Infection › Co-infection › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Phénomènes microbiologiques › Phénomènes physiologiques viraux › Charge virale › Longitudinal viral shedding and antibody...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Chaîne d'infection › Réservoirs de maladies › Matières contaminées › Longitudinal viral shedding and antibody...